REGULATORY

• Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
  December 25, 2025

• Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
  December 25, 2025

• Japan Growth Strategy Council to Set Up Drug Discovery Working Group
  December 25, 2025

• Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
  December 25, 2025

• Japan Panel OKs Label Warning Update for Labor Inducers to Mention Epidural Births
  December 25, 2025

• Japan Weighs Scrapping “Spillover” Rule in Shift from Draft Reform Outline
  December 24, 2025

• Heparinoid, Allergy Drugs among OTC-Like Meds Up for Special Charge Rule
  December 24, 2025

• Japan Hands Out Orphan Designation to 11 Drugs
  December 24, 2025

• Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
  December 23, 2025

• Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
  December 23, 2025

• Japan Drops Transitional Plan for PCV20 Routine Shot in Elderly
  December 23, 2025

• Tecartus Now in Line for Orphan Status with Japan Panel Nod
  December 23, 2025

• LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
  December 22, 2025

• Japan Set to Raise Medical Fees by 3% in FY2026, Cut Drug Prices by 0.8%
  December 22, 2025

• LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
  December 22, 2025

• OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
  December 19, 2025

• LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
  December 18, 2025

• Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
  December 18, 2025

• Panel to Weigh Orphan Designation for Tecartus on December 22
  December 17, 2025

• LDP League Formally Urges Male HPV Shots Under NIP from FY2026
  December 17, 2025

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »